• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在双目间接检眼镜检查中降低散瞳剂不良反应的风险

Minimizing risk of adverse reactions to mydriatic agents in binocular indirect ophthalmoscopy.

作者信息

Levine L

出版信息

J Am Optom Assoc. 1985 Jul;56(7):542-8.

PMID:4020007
Abstract

To minimize the risk of adverse side effects from mydriatics during binocular indirect ophthalmoscopy, a procedure was developed which intentionally starts with a dose significantly less than an ED99. Using a clinically effective diameter of greater than 7 mm as a criterion, I found that 1 drop of 0.5% tropicamide (T) constituted an ED74 (N = 46). When 1 drop of 2.5% phenylephrine (P) was added, this increased to an ED93 (N = 27). If present results can be generalized, then 1 drop of T, supplemented at 30 minutes with 1 drop of P, if necessary, should produce satisfactory dilatation in approximately 90% of the subjects.

摘要

为了将双目间接检眼镜检查期间使用散瞳剂产生副作用的风险降至最低,我们开发了一种程序,该程序有意从显著低于ED99的剂量开始。以大于7mm的临床有效直径为标准,我发现1滴0.5%托吡卡胺(T)构成ED74(N = 46)。当添加1滴2.5%去氧肾上腺素(P)时,这增加到ED93(N = 27)。如果目前的结果可以推广,那么1滴T,如果必要的话,在30分钟后补充1滴P,应该能在大约90%的受试者中产生令人满意的散瞳效果。

相似文献

1
Minimizing risk of adverse reactions to mydriatic agents in binocular indirect ophthalmoscopy.在双目间接检眼镜检查中降低散瞳剂不良反应的风险
J Am Optom Assoc. 1985 Jul;56(7):542-8.
2
A combination solution for routine pupillary dilation.一种用于常规瞳孔扩张的复方溶液。
Optometry. 2006 Jul;77(7):350-3. doi: 10.1016/j.optm.2006.04.107.
3
Single dose of 1% tropicamide and 10% phenylephrine for pupil dilation.单次使用1%托吡卡胺和10%去氧肾上腺素进行散瞳。
J Med Assoc Thai. 2006 Nov;89(11):1934-9.
4
Mydriatic and cardiovascular effects of phenylephrine 2.5% versus phenylephrine 10%, both associated with tropicamide 1%.2.5%去氧肾上腺素与10%去氧肾上腺素联合1%托吡卡胺的散瞳和心血管效应
Ophthalmic Res. 2009;42(2):87-9. doi: 10.1159/000220601. Epub 2009 May 27.
5
Comparison of efficacy and tolerance between 1% hydroxyamphetamine plus 0.25% tropicamide (Paremyd) and 0.5% tropicamide combined with 2.5% phenylephrine.1% 羟苯丙胺加 0.25% 托吡卡胺(派立明)与 0.5% 托吡卡胺联合 2.5% 去氧肾上腺素的疗效及耐受性比较。
J Am Optom Assoc. 1996 Nov;67(11):681-9.
6
A clinical comparison of mydriatics.散瞳剂的临床比较
J Am Optom Assoc. 1983 Sep;54(9):781-4.
7
Comparison between obtained mydriasis in type 2 diabetics and non-diabetic patients.2 型糖尿病患者与非糖尿病患者散瞳效果的比较。
Curr Eye Res. 2009 Nov;34(11):925-7. doi: 10.3109/02713680903205220.
8
A double-blind study comparing 0.5% and 1% tropicamide for annual retinal screening in diabetic adolescents.一项比较0.5%和1%托吡卡胺用于糖尿病青少年年度视网膜筛查的双盲研究。
Diabet Med. 2004 May;21(5):434-9. doi: 10.1111/j.1464-5491.2004.01172.x.
9
Comparative pupil dilation using phenylephrine alone or in combination with tropicamide.单独使用去氧肾上腺素或与托吡卡胺联合使用时的瞳孔扩张比较。
Ophthalmology. 1998 Apr;105(4):726-32. doi: 10.1016/S0161-6420(98)94030-1.
10
Effect of the single-drop mydriatic combination of 0.8% tropicamide with 5% phenylephrine with multiple applications of the same drop: a randomized controlled trial.
Indian J Ophthalmol. 2011 Jul-Aug;59(4):323-5. doi: 10.4103/0301-4738.82008.